Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Sanofi
47 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Vaccine
Sanofi and GSK to Support COVAX with 200 Million Doses of COVID-19 Vaccine
PR-M10-20-18
COVID-19 Vaccine Funding
Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 Vaccine
PR-M08-20-NI-05
Strategic Partnership
Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
PR-M07-20-NI-013
Collaboration
Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas
PR-M06-20-NI-027
FDA Approval
FDA Approves New Meningococcal Vaccination
PR-M04-20-NI-041
COVID-19 Clinical Trial
Sanofi and Regeneron Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial in Hospitalized COVID-19 Patients
PR-M04-20-NI-040
COVID-19 Self-Testing
Sanofi and Luminostics to Join Forces on Developing COVID-19 Smartphone-based Self-Testing Solution
PR-M04-20-NI-030
Sanofi and GSK to Join Forces in COVID-19 Vaccine Collaboration
PR-M04-20-NI-020
Diabetes
Sanofi to Exit Diabetes and Cardiovascular Research
PAO-M12-19-NI-005
M&A
Sanofi to Acquire Synthorx to Bolster its Immuno-Oncology Pipeline for $2.5 Billion
PR-M12-19-NI-016
PR-M09-19-NI-032
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
PR-M09-19-NI-032
Marketing
Visual Marketing Strategy for Libtayo
PAO-M08-19-NI-005
Market Growth
Sanofi Delivered Solid Growth in Q2 2019
PR-M07-19-NI-077
Influenza
Sanofi Signs Strategic Deal for Exclusive US Over-the-Counter Rights to Tamiflu® in Flu Care
PR-M07-19-NI-061
Restructure
Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
PR-M06-19-NI-032
Patent
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
PR-M02-19-NI-059
Appointment
Sanofi CEO Olivier Brandicourt Becomes PhRMA Board Chairman
PR-M02-19-NI-007
Immuno-oncology
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
PR-M01-19-NI-031
Immuno-oncology
Sanofi and Regeneron Immuno-oncology Collaboration Ending
PAO-M01-19-NI-012
New Facility
Sanofi to Consolidate Massachusetts Activities
PAO-M12-18-NI-017
Drug Development
EMA Recommends Approval of the First Oral Drug for Sleeping Sickness
PAO-M11-18-NI-019
Collaboration
Sanofi and Denali Therapeutics Enter New Collaboration
PAO-M11-18-NI-008
Vaccine
Positive Opinion Announced in EU for New Dengue Fever Vaccine
PAO-M10-18-NI-025
Approval
FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
PR-M10-18-NI-020
1
2
»
